Format

Send to

Choose Destination
Drug Discov Today. 2016 Jan;21(1):190-199. doi: 10.1016/j.drudis.2015.09.017. Epub 2015 Oct 9.

Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds.

Author information

1
Department of Internal Medicine, and Center of Excellence for Biomedical Research (CEBR), University of Genova, Viale Benedetto XV, 2-16132 Genova, Italy.
2
Department of Biosciences, University of Milano, 20122 Milano, Italy.
3
Department of Internal Medicine, and Center of Excellence for Biomedical Research (CEBR), University of Genova, Viale Benedetto XV, 2-16132 Genova, Italy. Electronic address: federica.barbieri@unige.it.

Abstract

Drug repositioning is gaining increasing attention in drug discovery because it represents a smart way to exploit new molecular targets of a known drug or target promiscuity among diverse diseases, for medical uses different from the one originally considered. In this review, we focus on known non-oncological drugs with new therapeutic applications in oncology, explaining the rationale behind this approach and providing practical evidence. Moving from incompleteness of the knowledge of drug-target interactions, particularly for older molecules, we highlight opportunities for repurposing compounds as cancer therapeutics, underling the biologically and clinically relevant affinities for new targets. Ideal candidates for repositioning can contribute to the therapeutically unmet need for more-efficient anticancer agents, including drugs that selectively target cancer stem cells.

PMID:
26456577
DOI:
10.1016/j.drudis.2015.09.017
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center